Premium
Efficacy and complications of adalimumab treatment for medically‐refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008)
Author(s) -
HO G. T.,
MOWAT A.,
POTTS L.,
CAHILL A.,
MOWAT C.,
LEES C. W.,
HARE N. C.,
WILSON J. A.,
BOULTONJONES R.,
PRIEST M.,
WATTS D. A.,
SHAND A. G.,
ARNOTT I. D.,
RUSSELL R. K.,
WILSON D. C.,
MORRIS A. J.,
SATSANGI J.
Publication year - 2009
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2008.03919.x
Subject(s) - medicine , adalimumab , infliximab , crohn's disease , refractory (planetary science) , regimen , perforation , adverse effect , gastroenterology , surgery , disease , physics , materials science , astrobiology , punching , metallurgy
Summary Background Adalimumab is a second generation humanized anti‐tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn’s disease (CD). Aims To evaluate the efficacy and safety of adalimumab on a nationwide clinical setting. Methods We used the Scottish Society of Gastroenterology network to identify and follow up the clinical outcomes of patients with CD treated with adalimumab over a 4‐year period (2004–2008). Results A total of 98 patients received adalimumab ‐ 100.5 patient follow‐up years were recorded (64.3% females; median age at diagnosis of 20.7 years; 88.8% treated with 80/40 mg induction regimen. Eighty eight (89.8%) had previous infliximab with 29 (32.9%) primary nonresponders; 32 (32.6%) were corticosteroid‐dependent; 47 (47.9%) were intolerant/resistant to most immunosuppressive therapies (two or more). In all, 60% of patients were in clinical remission at 1‐year follow‐up, with 30% and 55% requiring dose escalation to weekly therapy at 1‐and 2‐year follow‐up respectively. Overall, 29 (29.6%) patients developed complications with eight nonfatal serious (8.2%) adverse events and 2 (2.0%) case fatalities (sepsis following perforation and disseminated colorectal cancer, respectively). Conclusions Adalimumab is efficacious in severe and refractory CD in the clinical setting, although there remain significant therapy‐ and disease‐related risks of serious complications.